Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial

Study limitation reported by the research below: “Study population is exclusively Japanese; caution is warranted when extrapolating findings to other East Asian or non-Asian populations.”